I remember that in one of the CEO presentation(and further Q&A...

I remember that in one of the CEO presentation(and further Q&A session) there is the end point of a cost economic analysis for Germany and the UK. I mean the advantage of using Vitrogro against current standard treatment in Germany and the UK. As you are aware, the company is analysing from many years the world markets on VLU, DFU and PU. The management is very competent and actually based on the presentations, it is one of the company missions to be deeply involved in health economics of each specific market. I have recognised that the company is TOP CLASS in identifying and maximising market potentials. Just consider, that considering all the application variables of VITROGRO, (even cosmetics among the many), in the end they have concentrated at this stage company resources to VLU as, based on scientific evidence, this market is not tapped, it is open to innovations, and actually not with a cheap good cure and as today managed just with standard expensive care. This is a major cost for the patient and the health public sector, beside the huge pain and consequences that affect the patient. We know all well, that having a organ amputated is a nightmare both physically and emotionally.
The Market Research, done in these years, is a company asset that will pay very well in the long term, but it looks like nobody understand that research need to be focused on the best markets and applications, otherwise it is like jumping in an open OCEAN without a specific mission. The end without a clear objective is to die, and many biotech companies fail just because they concentrate just on the product and not in understanding properly a complex market.
Remember, that is very easy to get lost without proper focus and investor education is critical at this stage to understand a complex, but very high rewarding field, such as biotechnology.

For educational purposes, there some very interesting Research papers that evidence the benefits of Vitrogro and therefore (this is the luminare expression) a benefit in health economics both for the patient and the health sector.

The International Wound Journal in 2014 has come out with a specific topic on the theme and actually these are the details of VITROGRO clinical trials for the EU application and is equal/equivalent to a Phase 2 in the USA:
"
Effectiveness of an acellular synthetic matrix in the treatment of hard-to-heal leg ulcers
"
It is a specific medical Journal and you should buy the copy. I have not found a free copy for you on the Internet. Anyhow, it is a very good source of information on VITROGRO.
Prof. Keith Harding is the European President of The Wound Health Society. He is a top luminary in dermatology and wound management. He is a researcher at Cardiff University, and he has found VITROGRO such an excellent product that he is today one of Tissue Scientific Advisors.
You can see Keith Harding discussion on VITROGRO on YouTube ()

To buy the article, you can buy it at:

http://onlinelibrary.wiley.com/doi/10.1111/iwj.12115/full

http://www.ncbi.nlm.nih.gov/pubmed?
cmd=search&term=Gibb%20M%5Bau%5D&dispmax=50

http://ewma.org/fileadmin/user_uplo..._THE_TREATMENT_OF_HARD-TO-HEAL_LEG_ULCERS.pdf


Moreover, to better understand this market, there is a free but very interesting 2011 article on Wounds and specifically:
"
Acellular Matrices for the Treatment of Wounds
"
http://www.woundsinternational.com/pdf/content_9732.pdf

(it deals the protocols, current competitive products, risks, classifications and regulatory approval both for EU (EMA) and USA (FDA).

Another free useful 2014 article is:
"
Chronic Venous Ulcer: A comparative Effectiveness Review of Treatment Modalities
"
http://effectivehealthcare.ahrq.gov...ulcers-treatment-executive-erratum-140127.pdf

Moreover, Dr. Mercer discussed about health economics at the 2013 AGM and 2014 Presentations

http://www.tissuetherapies.com/uploads/CEO's Presentation AGM 2013.pdf

http://www.asx.com.au/spotlight/london/documents/presentations/Tissue_Therapies.pdf